Background
The first analysis of long-term exposures to air pollution and risk of mortality using the American Cancer Society Cancer Prevention Study II (ACS CPS-II) cohort was published in 1995. 1 Subsequently, extensive independent reanalysis 2 and multiple extended analyses [3] [4] [5] [6] [7] were conducted. These studies have consistently demonstrated that exposure to fine particulate matter air pollution (PM 2.5 ) is associated with increased risk of mortality, especially cardiopulmonary or cardiovascular disease mortality. A recent analysis by Enstrom, based on early data from the ACS CPS-II cohort, reports no significant relationship between PM 2.5 and total mortality. 8 The author asserts that the original analyses, reanalyses, and the extended analyses found positive PM 2.5 -mortality relationships because of selective use of CPS-II and PM 2.5 data.
Expanded Analyses of the ACS CPS-II Cohort
The assertion regarding selective use of the CPS-II and PM 2.5 data is false. The scope of analyses of the ACS CPS-II cohort conducted over more than 2 decades were explicitly expanded over time to characterize population health risks of PM 2.5 in more detail and with greater accuracy. Table 1 provides an outline of key published studies of this expansive body of air pollution research. The highlights of the obvious progress made during the course of these studies include the following: 1) increased mortality follow-up from 7 to 22 or 26 years; 2) increased number of participants included in the analyses from approximately 295 000 to 670 000; 3) increased number of deaths (a key determinant of study power) included in the analyses from approximately 21 000 to 237 000; 4) improved assessment of PM 2.5 exposures (and exposures of co-pollutants) from metro-level averages for cities with air pollution monitoring to modeled PM 2.5 exposures at geocoded residential addresses throughout the United States; and 5) improved statistical models, including improved control for individual and ecological covariates, and better representation of spatial patterns in the data.
As shown in Figure 1 , estimates of the percentage increase in mortality risk per 10 mg/m 3 increase in PM 2.5 for all-cause and for cardiovascular disease mortality from studies using the ACS CPS-II cohort have been remarkably consistent across the expanded analyses over the last 20þ years. The recent analysis by Enstrom 8 shows an estimated PM 2.5 -mortality association that is smaller than observed in the original analysis, the reanalysis, multiple subsequent extended analyses, or metaanalyses of studies throughout the world.
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Deficiencies in Enstrom's Reanalysis
Enstrom's recently published analysis 8 is the least advanced analysis of the ACS CPS-II cohort to date (see Table 1 ). The Enstrom's analysis uses a data set with a shorter follow-up period, fewer participants, and fewer deaths than any previous PM 2.5 -mortality analyses that used the CPS-II cohort, including the original 1995 analysis. He controls for a relatively limited number of individual-level covariates and does not control for any ecologic covariates. Moreover, the key deficiency in the Enstrom's reanalysis is the absence of advanced modeling approaches for exposure assessment that have been developed over the last 2 decades. Estimates of PM 2.5 -mortality associations are affected by the quality of the PM 2.5 data and the accuracy of matching participants and exposures. In a recent analysis, 7 we evaluated PM 2.5 exposures using multiple exposure assessment methods. Figure 1 illustrates that there were significant PM 2.5 -mortality risk associations for all PM 2.5 measures, but the associations were lower for the presumably less accurate measures that used remote sensing without ground-based data. Based on measures of model quality, the PM 2.5 exposure values that best fit (lowest Akaike Information Criteria, AIC) the data resulted in relatively larger PM 2.5 -mortality associations (see Figure 1) . In contrast, Enstrom 8 asserts that he estimates smaller PM 2.5 -mortality associations because he uses the "best" PM 2.5 data. He provides neither evidence in support of this assertion nor any measures of the relative quality of models using alternative PM 2.5 data. It is not clear how or why his "IPN" PM 2.5 data differ from the "Health Effects Institute" PM 2.5 data-especially given that these data come from the same monitoring network.
Furthermore, Enstrom's PM 2.5 exposure assessment is likely subject to greater exposure misclassification because of inadequate assignment of geographic units of exposure. Although other published ACS CPS-II studies assigned geographic areas of exposure based on participants' residence information, the Enstrom's analysis used the ACS Division and Unit numbers to assign PM 2.5 exposures (see letter from ACS). The ACS Division and Unit numbers, however, were for the ACS volunteers that recruited the participants. These volunteers did not always live in the same area or even in the same state as the participants. Enstrom does not document the extent of this participant-exposure mismatching, but it has the potential for substantial exposure misclassification and resultant attenuation bias. Our published research using the ACS CPS-II data is based on participant-exposure matching that is accurate, includes highly spatially resolved exposure models, and utilizes ground-based monitoring and land use data.
An inexplicable deficiency of the Enstrom's article is its inadequate documentation of the relevant and extensive peerreviewed literature. References provided in the article largely 7 the highest quality models (those with the lowest AIC) produced the highest risk estimates; remote sensing models with no ground-based data produced the lowest risk estimates, likely because of greater exposure misclassification. (3) The lowest risk estimate reported by Enstrom 8 is based on a dated and short follow-up of the ACS cohort and is likely subject to exposure mismatching. ACS CPS II indicates American Cancer Society Cancer Prevention Study II; PM 2.5 , particulate matter air pollution.
include an unconventional mix of unpublished and non-peerreviewed correspondence (including letters, e-mails, and transcript of a teleconference call), presentation slides, press releases, and a compilation of manuscript rejections. Key published extended analyses of the ACS CPS-II cohort, 3, 5, 6, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] studies of other cohorts, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] or even major reviews and evaluations of the literature 32, 33 are not cited or discussed.
Broader Evidence
The PM 2.5 -mortality associations observed from the various analyses of the ACS CPS-II cohort are consistent with a much broader body of evidence from other studies. As examples, these include studies of other cohorts from the United States [19] [20] [21] [22] [23] [24] [25] [26] Europe, [27] [28] [29] and Canada. 30, 31 In addition, metaanalytic estimates of the PM 2.5 -mortality associations based on a 2013 meta-analysis of the overall literature 18 are also provided for comparison purposes in Figure 1 .
Previous studies of the ACS CPS-II cohort consistently demonstrated PM 2.5 -mortality associations with cardiovascular mortality. 7, 9 There has also been substantial work in exploring and understanding the biological pathways and mechanisms linking PM 2.5 exposures and cardiovascular disease and death. [32] [33] [34] [35] Similarly, the ACS CPS-II cohort has demonstrated PM 2.5 -mortality associations with lung cancer mortality, 3, 12, 14 and recently, the International Agency for Research on Cancer concluded, based on multiple sources of evidence, that particulate matter in outdoor air pollution is a cause of human lung cancer (group 1). 36 Enstrom 8 presents no results for cardiovascular or lung cancer mortality and largely dismisses the substantial and growing literature regarding relevant pathophysiological pathways and related biological mechanisms.
The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (conducted by the Institute for Health Metrics and Evaluation) identified ambient PM 2.5 air pollution as the 5th leading risk factor for global mortality, contributing to approximately 4.2 million deaths in 2015.
37, 38 These results are based on recent and comprehensive estimates from ACS CPS-II cohort studies and 23 other peer-reviewed studies of longterm exposure to PM 2.5 and mortality from cause-specific cardiovascular and respiratory disease and lung cancer. These results underscore the importance of PM 2.5 as a substantial determinant of mortality in the general population. Consequently, these results also suggest substantial health benefits from further reductions in ambient air pollution.
In summary, we welcome thoughtful criticism of our research. But the study by Enstrom does not contribute to the larger body of evidence on the health effects of PM 2.5 , as it does not utilize adequate approaches for exposure assessment, suitable methods for linking participants to exposure, and sufficient statistical control for potential confounding factors and fails to recognize the larger body of evidence on PM 2.5 exposure and disease risk.
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